These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17317203)

  • 1. Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?
    Biganzoli L; Claudino WM; Pestrin M; Pozzessere D; Di Leo A
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):1-8. PubMed ID: 17317203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
    Montemurro F; Aglietta M
    Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for early-stage breast cancer.
    McArthur HL; Hudis CA
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).
    Kim R; Tanabe K; Uchida Y; Osaki A; Toge T
    Oncol Rep; 2002; 9(1):3-9. PubMed ID: 11748447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
    Petrelli F; Cabiddu M; Ghilardi M; Barni S
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?
    Chiuri VE; Lorusso V
    Oncology; 2009; 77 Suppl 1():18-22. PubMed ID: 20130428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
    Tsakonas G; Kosmas C
    J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
    Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R
    Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy.
    Andre F; Pusztai L
    Nat Clin Pract Oncol; 2006 Nov; 3(11):621-32. PubMed ID: 17080180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
    J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL;
    J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
    Pusztai L; Broglio K; Andre F; Symmans WF; Hess KR; Hortobagyi GN
    J Clin Oncol; 2008 Oct; 26(28):4679-83. PubMed ID: 18662965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Andersson M; Kamby C
    Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological therapy of breast cancer: recent clinical applications.
    Baar J
    Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.